Antibe Therapeutics (STU:4B70) EBIT: €-12.57 Mil (TTM As of Dec. 2023)

What is Antibe Therapeutics EBIT?

Antibe Therapeutics STU:4B70 10 EBIT is €-12.57 Mil as of Dec. 2023. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

Antibe Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was €-2.88 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was €-12.57 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Antibe Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -62.83%. Antibe Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,453.38%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Antibe Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 47.56%.

Antibe Therapeutics (STU:4B70) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Antibe Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-12.564 * ( 1 - 0% )	/	( (20.403	+	19.59)	/ 2 )
=	-12.564	/	19.9965
=	-62.83 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.691	-	1.984	-	( 19.304	-	max(0, 1.984	-	21.536	+	19.304	))
=	20.403

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	38.524	-	1.91	-	( 17.024	-	max(0, 1.91	-	19.203	+	17.024	))
=	19.59

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Antibe Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.512	/	( ( (0 + max(0.248, 0))	+	(0 + max(0.269, 0)) )	/	2 )
=	-11.512	/	( ( 0.248	+	0.269 )	/	2 )
=	-11.512	/	0.2585
=	-4,453.38 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.232)	-	(1.984	+	0	+	0)
=	0.248

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	2.179)	-	(1.91	+	0	+	0)
=	0.269

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Antibe Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-12.569	/	-26.430
	=	47.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics EBIT Related Terms

Antibe Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's EBIT can be seen below:

Antibe Therapeutics EBIT Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT

Get a 7-Day Free Trial

-8.11

-12.03

-15.94

-18.10

-13.16

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															-2.92	-2.21	-4.02	-3.47	-2.88

STU:4B70 vs VRTX, REGN, SGEN: EBIT Comparison

For the Biotechnology subindustry, Antibe Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's EV-to-EBIT falls into.

Save Embed

10GF Score

Antibe Therapeutics Inc STU:4B70

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Antibe Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.57 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-12.57 Mil mean?

Antibe Therapeutics (STU:4B70) has a EBIT of €-12.57 Mil as of Dec. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Antibe Therapeutics.

Is Antibe Therapeutics' EBIT too high?

Antibe Therapeutics' current EBIT is €-12.57 Mil. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Antibe Therapeutics' EBIT compare to VRTX and REGN?

Antibe Therapeutics' EBIT of €-12.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Antibe Therapeutics. Antibe Therapeutics's current EBIT is €-12.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Antibe Therapeutics stock overvalued right now?

Antibe Therapeutics (STU:4B70) has a current EBIT of €-12.57 Mil. The current EBIT is €-12.57 Mil. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current EBIT is €-12.57 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies XCNQ:ACOG XCNQ:GLAB TSXV:TTI TSX:TH TSXV:GSD TSX:MBX TSX:APS TSXV:CZO TSXV:COV TSXV:MSCL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website https://www.antibethera.com

Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.

10GF Score

Get the complete analysis for STU:4B70

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44

Price

View STU:4B70 Analysis

See EBIT data for all stocks →